288 related articles for article (PubMed ID: 26577300)
1. An ADC for Triple-Negative Breast Cancer.
Cancer Discov; 2016 Jan; 6(1):OF8. PubMed ID: 26577300
[TBL] [Abstract][Full Text] [Related]
2. Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer.
Bardia A; Mayer IA; Vahdat LT; Tolaney SM; Isakoff SJ; Diamond JR; O'Shaughnessy J; Moroose RL; Santin AD; Abramson VG; Shah NC; Rugo HS; Goldenberg DM; Sweidan AM; Iannone R; Washkowitz S; Sharkey RM; Wegener WA; Kalinsky K
N Engl J Med; 2019 Feb; 380(8):741-751. PubMed ID: 30786188
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer.
Bardia A; Mayer IA; Diamond JR; Moroose RL; Isakoff SJ; Starodub AN; Shah NC; O'Shaughnessy J; Kalinsky K; Guarino M; Abramson V; Juric D; Tolaney SM; Berlin J; Messersmith WA; Ocean AJ; Wegener WA; Maliakal P; Sharkey RM; Govindan SV; Goldenberg DM; Vahdat LT
J Clin Oncol; 2017 Jul; 35(19):2141-2148. PubMed ID: 28291390
[TBL] [Abstract][Full Text] [Related]
4. Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics.
Ocean AJ; Starodub AN; Bardia A; Vahdat LT; Isakoff SJ; Guarino M; Messersmith WA; Picozzi VJ; Mayer IA; Wegener WA; Maliakal P; Govindan SV; Sharkey RM; Goldenberg DM
Cancer; 2017 Oct; 123(19):3843-3854. PubMed ID: 28558150
[TBL] [Abstract][Full Text] [Related]
5. Antibody-drug conjugates targeting TROP-2 and incorporating SN-38: A case study of anti-TROP-2 sacituzumab govitecan.
Goldenberg DM; Sharkey RM
MAbs; 2019; 11(6):987-995. PubMed ID: 31208270
[TBL] [Abstract][Full Text] [Related]
6. Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody-Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers.
Cardillo TM; Govindan SV; Sharkey RM; Trisal P; Arrojo R; Liu D; Rossi EA; Chang CH; Goldenberg DM
Bioconjug Chem; 2015 May; 26(5):919-31. PubMed ID: 25915780
[TBL] [Abstract][Full Text] [Related]
7. Sacituzumab govitecan: breakthrough targeted therapy for triple-negative breast cancer.
Weiss J; Glode A; Messersmith WA; Diamond J
Expert Rev Anticancer Ther; 2019 Aug; 19(8):673-679. PubMed ID: 31398063
[No Abstract] [Full Text] [Related]
8. Sacituzumab govitecan: antibody-drug conjugate in triple-negative breast cancer and other solid tumors.
Fenn KM; Kalinsky K
Drugs Today (Barc); 2019 Sep; 55(9):575-585. PubMed ID: 31584574
[TBL] [Abstract][Full Text] [Related]
9. Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer.
Bardia A; Hurvitz SA; Tolaney SM; Loirat D; Punie K; Oliveira M; Brufsky A; Sardesai SD; Kalinsky K; Zelnak AB; Weaver R; Traina T; Dalenc F; Aftimos P; Lynce F; Diab S; Cortés J; O'Shaughnessy J; Diéras V; Ferrario C; Schmid P; Carey LA; Gianni L; Piccart MJ; Loibl S; Goldenberg DM; Hong Q; Olivo MS; Itri LM; Rugo HS;
N Engl J Med; 2021 Apr; 384(16):1529-1541. PubMed ID: 33882206
[TBL] [Abstract][Full Text] [Related]
10. Sacituzumab govitecan-hziy for triple-negative breast cancer.
Stirrups R
Lancet Oncol; 2019 Apr; 20(4):e194. PubMed ID: 30827748
[No Abstract] [Full Text] [Related]
11. TROPiCS-02: A Phase III study investigating sacituzumab govitecan in the treatment of HR+/HER2- metastatic breast cancer.
Rugo HS; Bardia A; Tolaney SM; Arteaga C; Cortes J; Sohn J; Marmé F; Hong Q; Delaney RJ; Hafeez A; André F; Schmid P
Future Oncol; 2020 Apr; 16(12):705-715. PubMed ID: 32223649
[TBL] [Abstract][Full Text] [Related]
12. First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors.
Starodub AN; Ocean AJ; Shah MA; Guarino MJ; Picozzi VJ; Vahdat LT; Thomas SS; Govindan SV; Maliakal PP; Wegener WA; Hamburger SA; Sharkey RM; Goldenberg DM
Clin Cancer Res; 2015 Sep; 21(17):3870-8. PubMed ID: 25944802
[TBL] [Abstract][Full Text] [Related]
13. Sacituzumab govitecan (Trodelvy) for metastatic triple-negative breast cancer.
Med Lett Drugs Ther; 2021 Feb; 63(1617):e25-e27. PubMed ID: 33757114
[No Abstract] [Full Text] [Related]
14. Enhanced Delivery of SN-38 to Human Tumor Xenografts with an Anti-Trop-2-SN-38 Antibody Conjugate (Sacituzumab Govitecan).
Sharkey RM; McBride WJ; Cardillo TM; Govindan SV; Wang Y; Rossi EA; Chang CH; Goldenberg DM
Clin Cancer Res; 2015 Nov; 21(22):5131-8. PubMed ID: 26106073
[TBL] [Abstract][Full Text] [Related]
15. Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC).
Goldenberg DM; Cardillo TM; Govindan SV; Rossi EA; Sharkey RM
Oncotarget; 2015 Sep; 6(26):22496-512. PubMed ID: 26101915
[TBL] [Abstract][Full Text] [Related]
16. Sacituzumab Govitecan: First Approval.
Syed YY
Drugs; 2020 Jul; 80(10):1019-1025. PubMed ID: 32529410
[TBL] [Abstract][Full Text] [Related]
17. Sacituzumab govitecan activity in advanced breast cancer.
Burki TK
Lancet Oncol; 2017 May; 18(5):e246. PubMed ID: 28343977
[No Abstract] [Full Text] [Related]
18. Sacituzumab for the treatment of triple-negative breast cancer: the poster child of future therapy?
Zangardi ML; Spring LM; Nagayama A; Bardia A
Expert Opin Investig Drugs; 2019 Feb; 28(2):107-112. PubMed ID: 30507322
[TBL] [Abstract][Full Text] [Related]
19. Therapy of Advanced Non-Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan.
Heist RS; Guarino MJ; Masters G; Purcell WT; Starodub AN; Horn L; Scheff RJ; Bardia A; Messersmith WA; Berlin J; Ocean AJ; Govindan SV; Maliakal P; Mudenda B; Wegener WA; Sharkey RM; Goldenberg DM; Camidge DR
J Clin Oncol; 2017 Aug; 35(24):2790-2797. PubMed ID: 28548889
[TBL] [Abstract][Full Text] [Related]
20. Sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2, shows cytotoxic activity against poorly differentiated endometrial adenocarcinomas in vitro and in vivo.
Perrone E; Manara P; Lopez S; Bellone S; Bonazzoli E; Manzano A; Zammataro L; Bianchi A; Zeybek B; Buza N; Tymon-Rosario J; Altwerger G; Han C; Menderes G; Huang GS; Ratner E; Silasi DA; Azodi M; Hui P; Schwartz PE; Scambia G; Santin AD
Mol Oncol; 2020 Mar; 14(3):645-656. PubMed ID: 31891442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
